You have read all your free articles, to continue reading subscribe to read the rest of this content.
Scandion Oncology A/S has obtained DKK 5 million from Innovation Fund Denmark for the clinical development of SCO-101 in metastatic pancreatic cancer. The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic canAlready a subscriber Login You…
The two companies have entered into an agreement to create a global biosolutions partner through a statutory merger. The proposed combination of Novozymes and Chr. Hansen will create a group with a broad biological toolbox and a diversified portfolio across markets, the companies state. TogetherAlready a subscriber Login You have read…
Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen. The private placement enables acceleration of new projects in collaboration with an unnamed license partner as well as the building oAlready a subscriber Login You have read all your…
The company announces the completion of series A round of financing, intended to provide funds for completion of pre-clinical development of its lead candidate, GS-248. A consortium of seasoned life sciences investors will provide financial and strategic support to the development program and briAlready a subscriber Login You have read…
